Article
LEKTI domain 6 displays anti-inflammatory action in vitro and in a murine atopic dermatitis model
2023-04-17
Abstract excerpt
Background: Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a serine protease inhibitor consisting of multiple domains. A loss of function mutation is described in Netherton patients that show severe symptoms of atopic lesions and itch. <h4>Objectives:</h4> LEKTI domain 6 (LD6) has shown strong serine protease-inhibitory action in in vitro assays and thus it was tested in vitro and in vivo for potenti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 01ad4536-62b3-5417-accc-b49c56aeca29
- DOI
- 10.22541/au.168170955.51009089/v1
